3-V Biosciences garners $30M in venture funds

A start-up biotech company focused on infectious diseases and founded in part by Kleiner Perkins Caufield & Byers has rounded up $30 million in new investment capital to fund its next stage of development. 3-V Biosciences says New Enterprise Associates led the Series B, which also included the participation of Kleiner Perkins and The Column Group.

"This funding will enable 3-V Biosciences to continue advancing our mission to develop drugs that will transform the therapeutic paradigm for infectious diseases," said CEO Dr. John Curnutte. David Mott, general partner at NEA, was named chairman of the board, succeeding Richard Klausner, M.D. 3-V's original laboratory was opened in Zürich, close to the company's founders at the Swiss Federal Institute of Technology and the University of Zürich.

"3-V Biosciences is advancing an innovative scientific strategy that targets the host pathways required for infection. This approach could offer major advantages over traditional pathogen-directed therapies including the potential for broad spectrum activity and lower risk of drug resistance," said Mott.

- check out the press release

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.